- JP-listed companies
- SANTEN PHARMACEUTICAL CO.,LTD.
SANTEN PHARMACEUTICAL CO.,LTD.JP:4536
Market cap
¥636.6B
P/E ratio
34.1x
Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2023 | Mar 31, 2024 | |
Net sales | 119,066 | 148,663 | - | - | - | - | - | - | - | 196,589 | 195,238 |
Cost of sales | 41,501 | 58,104 | 56,373 | 72,829 | 74,966 | - | - | - | - | 87,415 | 92,062 |
Gross profit (loss) | 77,564 | 90,558 | 105,458 | 122,463 | 124,130 | - | - | - | - | 109,174 | 103,176 |
Selling, general and administrative expenses | 52,883 | 63,144 | - | - | - | - | - | - | - | 84,376 | 75,164 |
Operating profit (loss) | 24,681 | 27,414 | - | - | - | - | - | - | - | 24,798 | 28,013 |
Interest and dividend income | - | - | - | - | - | - | - | - | - | 499 | 536 |
Dividend income of life insurance | 157 | 147 | - | - | - | - | - | - | - | 155 | 157 |
Gain on valuation of derivatives | - | - | - | - | - | - | - | - | - | 52 | 232 |
Income of usage charge | - | - | - | - | - | - | - | - | - | 1,742 | 3,196 |
Other | 235 | 225 | - | - | - | - | - | - | - | 152 | 156 |
Non-operating income | 1,007 | 975 | - | - | - | - | - | - | - | 2,600 | 4,279 |
Interest expenses | 6 | 5 | - | - | - | - | - | - | - | 100 | 222 |
Foreign exchange losses | - | 222 | - | - | - | - | - | - | - | 39 | 248 |
Commission for purchase of treasury shares | 25 | - | - | - | - | - | - | - | - | 73 | 29 |
Litigation expenses | - | - | - | - | - | - | - | - | - | 51 | 410 |
Cancellation penalty | - | - | - | - | - | - | - | - | - | 45 | - |
Other | 54 | 18 | - | - | - | - | - | - | - | 21 | 110 |
Non-operating expenses | 86 | 465 | - | - | - | - | - | - | - | 330 | 1,019 |
Ordinary profit (loss) | 25,602 | 27,924 | - | - | - | - | - | - | - | 27,068 | 31,272 |
Gain on disposal of non-current assets | 17 | - | - | - | - | - | - | - | - | 3 | 2 |
Gain on sale of investment securities | - | 473 | - | - | - | - | - | - | - | 1,599 | 1,912 |
Extraordinary income | 17 | 473 | - | - | - | - | - | - | - | 1,602 | 1,915 |
Loss on disposal of non-current assets | 26 | 27 | - | - | - | - | - | - | - | 23 | 24 |
Impairment losses | - | 94 | - | - | - | - | - | - | - | 747 | - |
Loss on disaster | - | - | - | - | - | - | - | - | - | - | 755 |
Loss on valuation of shares of subsidiaries and associates | - | - | - | - | - | - | - | - | - | 77,779 | - |
Provision of allowance for doubtful accounts for subsidiaries and associates | - | - | - | - | - | - | - | - | - | - | 1,997 |
Business restructuring expenses | - | - | - | - | - | - | - | - | - | - | 4,609 |
Extraordinary losses | 28 | 1,504 | - | - | - | - | - | - | - | 78,549 | 7,384 |
Profit before income taxes | 25,591 | 26,893 | - | - | - | - | - | - | - | -49,879 | 25,803 |
Income taxes - current | 7,908 | 11,762 | - | - | - | - | - | - | - | 6,397 | 6,529 |
Income taxes for prior periods | - | - | - | - | - | - | - | - | - | 2,632 | - |
Income taxes - deferred | 1,162 | -1,978 | - | - | - | - | - | - | - | 471 | 595 |
Income taxes | 9,070 | 9,783 | - | - | - | - | - | - | - | 9,501 | 7,123 |
Profit (loss) | - | - | 24,032 | 53,373 | 23,054 | - | - | - | - | -59,379 | 18,680 |